Adult urologyThe so-called “placebo effect” in benign prostatic hyperplasia treatment trials represents partially a conditional regression to the mean induced by censoring
References (31)
- et al.
The American Urological Association's symptom index for benign prostatic hyperplasia
J Urol
(1992) - et al.
The safety, efficacy and compliance of terazosin therapy for benign prostatic hyperplasia
J Urol
(1992) - et al.
A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia
J Urol
(1992) - et al.
Alfuzosin for treatment of benign prostatic hypertrophy: the BPH-ALF group
Lancet
(1991) - et al.
Effectiveness and safety of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia in the HYCAT study
Urology
(1996) - et al.
Current status of thermotherapy of the prostate
J Urol
(1997) - et al.
Sham versus transurethral microwave thermotherapy in patients with symptoms of benign prostatic bladder outflow obstruction
Lancet
(1993) - et al.
Transurethral microwave thermotherapy (TUMT) in benign prostatic hyperplasia: placebo versus TUMT
Urology
(1994) - et al.
A sham controlled trial of transurethral microwave therapy with subsequent treatment of the control group
J Urol
(1994) - et al.(1994)
Measuring disease-specific health status in men with benign prostatic hyperplasia
Med Care
(1995)
The placebo effect in medical and psychological therapies
Placebo effect: an examination of Grunbaum's definition
Placebo in perspective
Cited by (0)
Copyright © 1998 Published by Elsevier Inc.